http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021235436-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7d9efad87e0fb61ac65777be53aa204
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
filingDate 2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d394e032def5f0fca7e243475c5d7fe4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b8e25429baa26e90391c9b5bf361d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d41dc1255f870d44ee10efbf3459f01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_465603ca414c7fda19ce5bac23a4c3bc
publicationDate 2021-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021235436-A1
titleOfInvention Apomorphine-containing percutaneous absorption type preparation
abstract The present invention addresses the problem of providing a percutaneous absorption type preparation that, as a result of having apomorphine hydrochloride dissolved therein at a high concentration, allows rapid absorption of apomorphine in an amount sufficient for medical treatment, and also allows for continuous administration of apomorphine. An example of the present invention is a percutaneous absorption type preparation that contains apomorphine or a salt thereof, polyalcohol with not more than six carbons and/or low-molecular-weight polyethylene glycol, and propylene carbonate. The present invention makes it possible to prepare a high-concentration apomorphine-containing solution, which allows rapid percutaneous absorption of a sufficient amount of apomorphine into the body, and also allows for continuous administration of apomorphine.
priorityDate 2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017081947-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011511088-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9619956-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015151380-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002087954-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013213035-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399704
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399716

Total number of triples: 39.